NBIX FY 2020 Earnings Report — Neurocrine Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

Neurocrine Biosciences, Inc.NBIX

FY 2020 Earnings

Reported February 5, 2021

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2020	Prior Q	FY 2019	QoQ Change	YoY Change
Revenue	$1.0B	—	$788M	—	32.7%
Op. Income	$163M	—	$72M	—	125.4%
Gross Margin	99.0%	—	99.1%	—	-0.0pp
Net Margin	38.9%	—	4.7%	—	34.2pp
EPS (Diluted)	$4.16	—	$0.39	—	966.7%
Free Cash Flow	$218M	—	$132M	—	64.5%

Revenue Flow

Item	Amount
REVENUE	$1.0B
Cost of Revenue	$10M
GROSS PROFIT	$1.0B
R&D Expenses	$275M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$433M
Other Expenses	$165M
Operating Expenses	$873M
Cost & Expenses	$883M
OPERATING INCOME	$163M
Interest Income	$0
Interest Expense	$33M
Other Income/Expenses	-$56M
INCOME BEFORE TAX	$107M
Income Tax Expense	-$301M
Net Income from Continuing Ops	$407M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$407M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$407M
D&A	$9M
EBIT	$140M
EBITDA	$148M
EPS	$4
EPS Diluted	$4

Income Statement

Item	Amount
REVENUE	$1.0B
Cost of Revenue	$10M
GROSS PROFIT	$1.0B
R&D Expenses	$275M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$433M
Other Expenses	$165M
Operating Expenses	$873M
Cost & Expenses	$883M
OPERATING INCOME	$163M
Interest Income	$0
Interest Expense	$33M
Other Income/Expenses	-$56M
INCOME BEFORE TAX	$107M
Income Tax Expense	-$301M
Net Income from Continuing Ops	$407M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$407M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$407M
D&A	$9M
EBIT	$140M
EBITDA	$148M
EPS	$4
EPS Diluted	$4

Cash Flow Statement

Item	Amount
Net Income	$407M
Depreciation & Amortization	$9M
Stock-Based Compensation	$100M
Deferred Income Tax	-$311M
Other Non-Cash Items	$61M
Change in Working Capital	-$38M
OPERATING CASH FLOW	$229M
Capital Expenditure	-$11M
Acquisitions (Net)	$0
Purchases of Investments	-$736M
Sales/Maturities of Investments	$751M
Other Investing Activities	$0
NET CASH FROM INVESTING	$4M
Net Debt Issuance	-$187M
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	-$158M
FREE CASH FLOW	$218M
Net Change in Cash	$75M

Balance Sheet

Item	Amount
Cash & Equivalents	$187M
Short-Term Investments	$614M
Net Receivables	$157M
Inventory	$28M
Other Current Assets	$30M
TOTAL CURRENT ASSETS	$1.0B
PP&E (Net)	$127M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$265M
Tax Assets	$319M
Other Non-Current Assets	$6M
TOTAL NON-CURRENT ASSETS	$719M
TOTAL ASSETS	$1.7B
Account Payables	$39M
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$91M
TOTAL CURRENT LIABILITIES	$187M
Long-Term Debt	$318M
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$10M
TOTAL NON-CURRENT LIABILITIES	$422M
TOTAL LIABILITIES	$609M
Common Stock	$100.0K
Additional Paid-In Capital	$1.8B
Retained Earnings	-$725M
Treasury Stock	$0
Accum. Other Comp. Income	$2M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$1.1B
Minority Interest	$0
TOTAL EQUITY	$1.1B
TOTAL LIABILITIES & EQUITY	$1.7B
Total Debt	$412M
Net Debt	$225M